The Potassium Competitive Acid Blocker P Cab Market continues to expand as gastroenterologists, surgeons, and critical care physicians increasingly embrace this novel class of acid-suppressing agents for managing acid-related disorders with faster onset and more potent inhibition compared to traditional proton pump inhibitors. With P-CABs such as vonoprazan, tegoprazan, and fexuprazan...